Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Cash & Current Investments: 2021-2024

Historic Cash & Current Investments for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $314.0 million.

  • ARS Pharmaceuticals' Cash & Current Investments rose 40.85% to $288.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 27.73%. This contributed to the annual value of $314.0 million for FY2024, which is 37.51% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Cash & Current Investments of $314.0 million as of FY2024, which was up 37.51% from $228.4 million recorded in FY2023.
  • In the past 5 years, ARS Pharmaceuticals' Cash & Current Investments ranged from a high of $314.0 million in FY2024 and a low of $60.1 million during FY2021.
  • For the 3-year period, ARS Pharmaceuticals' Cash & Current Investments averaged around $272.3 million, with its median value being $274.4 million (2022).
  • In the last 5 years, ARS Pharmaceuticals' Cash & Current Investments soared by 356.82% in 2022 and then decreased by 16.77% in 2023.
  • Over the past 4 years, ARS Pharmaceuticals' Cash & Current Investments (Yearly) stood at $60.1 million in 2021, then skyrocketed by 356.82% to $274.4 million in 2022, then decreased by 16.77% to $228.4 million in 2023, then soared by 37.51% to $314.0 million in 2024.